黄褐斑发病机制最新研究进展

doi:10.3969/j.issn.2097-0005.2021.06.022

摘要/Abstract

摘要： 黄褐斑为面部对称性黄褐色色素沉着斑,相对常见且易复发,严重影响患者的外观和心理健康。黄褐斑的病因及发病机制复杂,国内外学者对其发病机制进行了不断的研究。尽管存在争议,但大多数学者认为遗传学、紫外线(UV)暴露和性激素水平在启动和维持色素表型方面起着关键的作用。最近研究发现,真皮因素、microRNAs(miRNAs)、氧自由基(ROS)在促进黄褐斑的发生发展中也起着一定作用。为进一步研究黄褐斑发病的可能因素,并对黄褐斑的预防、治疗及减少复发提供帮助,故就黄褐斑的病因和最新发病机制作一综述,重点介绍遗传易感性、紫外线暴露、激素水平、ROS及真皮因素在黄褐斑发病中的作用。

关键词: 黄褐斑, 遗传, 紫外线, 氧自由基(ROS), 可见光, 血管因素皮肤屏障, 微生物, 药物

中图分类号:

R751

吴嘉惠, 刘志超. 黄褐斑发病机制最新研究进展[J]. betway必威登陆网址（betway.com ）学报, 2021, 42(6): 471-475.

参考文献

[1] D'Elia MP,Brand o MC,de Andrade Ramos BR,et al.African ancestry is associated with facial melasma in women: a cross-sectional study[J].BMC Med Genet, 2017,18(1):17.
[2] Holmo NF, Ramos GB, Salom o H, et al.Complex segregation analysis of facial melasma in Brazil: evidence for a genetic susceptibility with a dominant pattern of segregation[J].Arch Dermatol Res,2018,310(10):827-831.
[3] Suryaningsih BE,Sadewa AH,Wirohadidjojo YW,et al.Association between heterozygote Val92MetMC1R gene polymorphisms with incidence of melasma: a study of Javanese women population in Yogyakarta[J].Clin Cosmet Investig Dermatol,2019,12:489-495.
[4] Handa S, De D, Khullar G,et al.The clinicoaetiological, hormonal and histopathological characteristics of melasma in men[J].Clin Exp Dermatol,2018,43(1):36-41.
[5] Sun Min,Xie Hong-Fu,Tang Yan, et al.G protein-coupled estrogen receptor enhances melanogenesis via cAMP-protein kinase (PKA) by upregulating microphthalmia-related transcription factor-tyrosinase in melanoma[J]. The Journal of steroid biochemistry and molecular biology,2017,165.
[6] Campuzano-García AE, Torres-Alvarez B, Hernández-Blanco D, et al.DNA Methyltransferases in Malar Melasma and Their Modification by Sunscreen in Combination with 4% Niacinamide, 0.05% Retinoic Acid, or Placebo[J].Biomed Res Int,2019:9068314.
[7] Mione M, Bosserhoff A. MicroRNAs in melanocyte and melanoma biology[J].Pigment Cell Melanoma Res,2015,28(3):340-354
[8] Kim NH, Choi SH, Yi N,et al.Arginase-2, a miR-1299 target, enhances pigmentation in melasma by reducing melanosome degradation via senescence-induced autophagy inhibition[J].Pigment Cell Melanoma Res,2017,30(6):521-530.
[9] Urbanelli L, Buratta S, Sagini K,et al.Exosome-based strategies for Diagnosis and Therapy[J].Recent Pat CNS Drug Discov,2015,10(1):10-27.
[10] Campuzano-García AE, Torres-Alvarez B, Hernández-Blanco D,et al.DNA Methyltransferases in Malar Melasma and Their Modification by Sunscreen in Combination with 4% Niacinamide, 0.05% Retinoic Acid, or Placebo[J].Biomed Res Int, 2019,9068314.
[11] Kwon Soon-Hyo,Na Jung-Im,Choi Ji-Young,et al.Melasma: Updates and perspectives[J].Experimental dermatology,2019,28(6).
[12] Passeron T, Picardo M. Melasma, a photoaging disorder[J].Pigment Cell Melanoma Res,2018,31(4):461-465.
[13] Choi HR, Kang YA, Lee HS,et al.Disulfanyl peptide decreases melanin synthesis via receptor-mediated ERK activation and the subsequent downregulation of MITF and tyrosinase[J].Int J Cosmet Sci,2016,38(3):279-285.
[14] Kim M, Shibata T, Kwon S,et al.Ultraviolet-irradiated endothelial cells secrete stem cell factor and induce epidermal pigmentation[J].Sci Rep,2018,8(1):4235.
[15] Seo EY, Jin SP, Sohn KC,et al.UCHL1 Regulates Melanogenesis through Controlling MITF Stability in Human Melanocytes[J].J Invest Dermatol,2017,137(8):1757-1765.
[16] Taraz M, Niknam S, Ehsani AH.Tranexamic acid in treatment of melasma: A comprehensive review of clinical studies[J]Dermatol Ther,2017,30(3):10.
[17] Cho YH, Park JE, Lim DS,et al.Tranexamic acid inhibits melanogenesis by activating the autophagy system in cultured melanoma cells[J].J Dermatol Sci,2017,88(1):96-102.
[18] Kohli I, Chaowattanapanit S, Mohammad TF, et al. Synergistic effects of long-wavelength ultraviolet A1 and visible light on pigmentation and erythema[J].Br J Dermatol,2018,178(5):1173-1180.
[19] Boukari F, Jourdan E, Fontas E, et al.Prevention of melasma relapses with sunscreen combining protection against UV and short wavelengths of visible light: a prospective randomized comparative trial[J].J Am Acad Dermatol,2015,72(1):189-90.
[20] Randhawa M, Seo I, Liebel F,et al.Visible Light Induces Melanogenesis in Human Skin through a Photoadaptive Response[J].PLoS One,2015,10(6):1371.
[21] Ogbechie-Godec OA, Elbuluk N. Melasma: an Up-to-Date Comprehensive Review[J].Dermatol Ther (Heidelb),2017,7(3):305-318.
[22] Choubey V, Sarkar R, Garg V,et al.Role of oxidative stress in melasma: a prospective study on serum and blood markers of oxidative stress in melasma patients[J].Int J Dermatol,2017,56(9):939-943.
[23] Kwon SH, Hwang YJ, Lee SK,et al.Heterogeneous Pathology of Melasma and Its Clinical Implications[J].Int J Mol Sci,2016,17(6):824.
[24] Byun JW, Park IS, Choi GS,et al.Role of fibroblast-derived factors in the pathogenesis of melasma[J].Clin Exp Dermatol,2016,41(6):601-609.
[25] Kim M, Lee J, Park TJ, et al.Paracrine crosstalk between endothelial cells and melanocytes through clusterin to inhibit pigmentation[J].Exp Dermatol,2018,27(1):98-100.
[26] Regazzetti C, De Donatis GM, Ghorbel HH, et al. Endothelial Cells Promote Pigmentation through Endothelin Receptor B Activation[J].J Invest Dermatol,2015,135(12):3096-3104.
[27] Geddes ER, Stout AB, Friedman PM. Retrospective analysis of the treatment of melasma lesions exhibiting increased vascularity with the 595-nm pulsed dye laser combined with the 1927-nm fractional low-powered diode laser[J].Lasers Surg Med,2017,49(1):20-26.
[28] Li JY, Geddes ER, Robinson DM,et al.A review of melasma treatment focusing on laser and light devices[J].Semin Cutan Med Surg,2016,35(4):223-232.
[29] Espósito ACC, Brianezi G, de Souza NP,et al.Exploring pathways for sustained melanogenesis in facial melasma: an immunofluorescence study[J].Int J Cosmet Sci,2018,40(4):420-424.
[30] Rodríguez-Arámbula A, Torres-álvarez B, Cortés-García D, et al.CD4, IL-17, and COX-2 Are Associated With Subclinical Inflammation in Malar Melasma[J].Am J Dermatopathol,2015,37(10):761-766.
[31] Gao YL, Jia XX, Wang M, et al. Melanocyte activation and skin barrier disruption induced in melasma patients after 1064nm Nd:YAG laser treatment[J].Lasers Med Sci,2019,34(4):767-771.
[32] Gautam M, Patil S, Nadkarni N,et al.Histopathological comparison of lesional and perilesional skin in melasma: A cross-sectional analysis[J].Indian J Dermatol Venereol Leprol,2019,85(4):367-373.
[33] Sarkar R, Ailawadi P, Garg S. Melasma in Men: A Review of Clinical, Etiological, and Management Issues[J].J Clin Aesthet Dermatol,2018,11(2):53-59.
[34] Cakmak SK, zcan N, KlA, et al. Etiopathogenetic factors, thyroid functions and thyroid autoimmunity in melasma patients[J].Postepy Dermatol Alergol,2015,32(5):327-330.
[35] Rostami Mogaddam M, Iranparvar Alamdari M, Maleki N,et al. Evaluation of autoimmune thyroid disease in melasma[J].J Cosmet Dermatol,2015,14(2):167-171.
[36] Rostami Mogaddam M, Safavi Ardabili N, Iranparvar Alamdari M, et al. Evaluation of the serum zinc level in adult patients with melasma: Is there a relationship with serum zinc deficiency and melasma[J].J Cosmet Dermatol,2018,17(3):417-422.
[37] Sohn E.Skin microbiota's community effort[J].Nature,2018,563(7732):S91-S93.
[38] Locci-Molina N,Wang A,Kroumpouzos G. Melasma Improving Spontaneously upon Switching from a Combined Oral Contraceptive to a Hormone-releasing Intrauterine Device: A Report of Four Cases[J].Acta Derm Venereol,2015,95(5):624-625.
[39] Cohen PR.Topical Anti-Estrogen Therapy To Treat Melasma[J].J Clin Aesthet Dermatol,2017,10(6):16.
[40] Cohen PR.Melasma treatment: A novel approach using a topical agent that contains an anti-estrogen and a vascular endothelial growth factor inhibitor[J].Med Hypotheses,2017,101:1-5.